Gopten

Gopten is a prescription medication that contains the active ingredient trandolapril, an angiotensin‑converting enzyme (ACE) inhibitor. It is supplied in oral dosage form and is marketed in the European Union. Trandolapril works by blocking the conversion of angiotensin I to angiotensin II, which helps to lower blood pressure and reduce strain on the heart. Gopten is used under medical supervision for cardiovascular conditions and management.

Gopten (trandolapril) is indicated for several cardiovascular indications where reduction of blood pressure or cardiac workload is desired.

- Hypertension (high blood pressure) management, either as monotherapy or in combination with other antihypertensives. - Chronic heart failure, to improve symptoms and reduce hospitalization risk. - Post‑myocardial infarction therapy, as part of long‑term cardiovascular risk reduction. - Diabetic nephropathy adjunct, when blood pressure control is needed to slow renal progression. - Left ventricular dysfunction, as recommended by clinical guidelines.

The safety profile of trandolapril includes a range of observed adverse reactions, which are generally categorized by frequency and severity.

Common: - Cough, often dry and persistent. - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue or mild weakness.

Serious: - Angioedema affecting the face, lips, tongue or airway. - Severe hypotension leading to fainting or shock. - Acute kidney injury manifested by rapid rise in serum creatinine.

Before initiating Gopten, clinicians should evaluate several patient‑specific factors to minimize risk and ensure appropriate use.

- Assess renal function; dose adjustment may be required in moderate to severe impairment. - Monitor serum potassium and electrolytes, particularly when combined with potassium‑sparing diuretics or supplements. - Review history of angioedema or hypersensitivity to ACE inhibitors. - Use caution in patients with bilateral renal artery stenosis or severe aortic stenosis. - Evaluate for pregnancy; ACE inhibitors are generally contraindicated during the second and third trimesters. - Consider potential interactions with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can affect renal perfusion.

Trandolapril may interact with other medicines, altering its efficacy or increasing the likelihood of adverse effects.

Avoid: - Concomitant use with other ACE inhibitors, ARBs, or direct renin inhibitors due to additive risk of hyperkalaemia and renal dysfunction. - Potassium supplements or potassium‑sparing diuretics, which can precipitate dangerous hyperkalaemia. - Aliskiren in patients with diabetes or renal impairment, as this combination is contraindicated.

Use with caution: - NSAIDs, which may reduce antihypertensive effect and impair renal function. - Diuretics, especially loop or thiazide types, which can increase the risk of hypotension and electrolyte imbalance. - Lithium, as ACE inhibition may raise lithium concentrations and toxicity risk.